Consensus for the diagnosis, prognosis and treatment of feline mammary tumors / Consenso para o diagnóstico, prognóstico e tratamento de tumores mamários em felinos

Mammary neoplasms are described as the third most common type of feline tumor, after haematopoietic and skin tumors, and present a challenge for clinicians because the prognosis for feline mammary tumors ranges from guarded to poor. Thus, it is necessary to define new therapeutic approaches and establish more in-depth knowledge about this disease in felines. The main aspects of the diagnosis, prognosis and treatment of feline mammary neoplasia were discussed, aiming to standardize the criteria and to serve as a guide for pathologists and veterinary clinicians.(AU)

As neoplasias mamárias são descritas como o terceiro tipo mais frequente de tumor em felinos (após as neoplasias hematopoiéticas e cutâneas) e apresentam um desafio para os clínicos devido ao prognóstico, que varia de reservado a ruim. Assim, é necessário conhecer melhor essa doença em felinos e definir novas abordagens terapêuticas. Discutiu-se os principais aspectos de diagnóstico, prognóstico e tratamento da neoplasia mamária felina, com o objetivo de padronizar os critérios e servir de guia para patologistas e clínicos veterinários.(AU)

Consensus for the diagnosis, prognosis and treatment of feline mammary tumors / Consenso para o diagnóstico, prognóstico e tratamento de tumores mamários em felinos

Mammary neoplasms are described as the third most common type of feline tumor, after haematopoietic and skin tumors, and present a challenge for clinicians because the prognosis for feline mammary tumors ranges from guarded to poor. Thus, it is necessary to define new therapeutic approaches and establish more in-depth knowledge about this disease in felines. The main aspects of the diagnosis, prognosis and treatment of feline mammary neoplasia were discussed, aiming to standardize the criteria and to serve as a guide for pathologists and veterinary clinicians.(AU)

As neoplasias mamárias são descritas como o terceiro tipo mais frequente de tumor em felinos (após as neoplasias hematopoiéticas e cutâneas) e apresentam um desafio para os clínicos devido ao prognóstico, que varia de reservado a ruim. Assim, é necessário conhecer melhor essa doença em felinos e definir novas abordagens terapêuticas. Discutiu-se os principais aspectos de diagnóstico, prognóstico e tratamento da neoplasia mamária felina, com o objetivo de padronizar os critérios e servir de guia para patologistas e clínicos veterinários.(AU)

Consensus for the diagnosis, prognosis and treatment of feline mammary tumors / Consenso para o diagnóstico, prognóstico e tratamento de tumores mamários em felinos

Mammary neoplasms are described as the third most common type of feline tumor, after haematopoietic and skin tumors, and present a challenge for clinicians because the prognosis for feline mammary tumors ranges from guarded to poor. Thus, it is necessary to define new therapeutic approaches and establish more in-depth knowledge about this disease in felines. The main aspects of the diagnosis, prognosis and treatment of feline mammary neoplasia were discussed, aiming to standardize the criteria and to serve as a guide for pathologists and veterinary clinicians.

As neoplasias mamárias são descritas como o terceiro tipo mais frequente de tumor em felinos (após as neoplasias hematopoiéticas e cutâneas) e apresentam um desafio para os clínicos devido ao prognóstico, que varia de reservado a ruim. Assim, é necessário conhecer melhor essa doença em felinos e definir novas abordagens terapêuticas. Discutiu-se os principais aspectos de diagnóstico, prognóstico e tratamento da neoplasia mamária felina, com o objetivo de padronizar os critérios e servir de guia para patologistas e clínicos veterinários.

Consensus regarding the diagnosis, prognosis and treatment of canine mammary tumors: benign mixed tumors, carcinomas in mixed tumors and carcinosarcomas

Mammary neoplasms are the most frequent tumors in female dogs. Of these neoplasms, benign mixed tumors (BMTs) and carcinomas in mixed tumors (CMTs) represent a large proportion of small animal oncology diagnoses. Together with carcinosarcomas (CSs), these three neoplastic entities are characterized by the proliferation of benign or malignant epithelial, myoepithelial, and mesenchymal cells, depending on their histological types. This histological heterogeneity, in addition to their molecular heterogeneity, confers these tumors with distinct biological behavior, which results in the need for different clinical and therapeutic approaches. The present consensual document elucidates the oncological issues related to the diagnosis, prognosis, and treatment of BMTs, CMTs, and CSs of the canine mammary gland.

Consensus regarding the diagnosis, prognosis and treatment of canine mammary tumors: benign mixed tumors, carcinomas in mixed tumors and carcinosarcomas

Mammary neoplasms are the most frequent tumors in female dogs. Of these neoplasms, benign mixed tumors (BMTs) and carcinomas in mixed tumors (CMTs) represent a large proportion of small animal oncology diagnoses. Together with carcinosarcomas (CSs), these three neoplastic entities are characterized by the proliferation of benign or malignant epithelial, myoepithelial, and mesenchymal cells, depending on their histological types. This histological heterogeneity, in addition to their molecular heterogeneity, confers these tumors with distinct biological behavior, which results in the need for different clinical and therapeutic approaches. The present consensual document elucidates the oncological issues related to the diagnosis, prognosis, and treatment of BMTs, CMTs, and CSs of the canine mammary gland.(AU)

Consensus for the Diagnosis, Prognosis and Treatment of Canine Mammary Tumors 2013

The purpose of this paper is to establish criteria that could guide the diagnosis, prognosis and treatment of caninemammary neoplasias. It was elaborated during the Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment ofthe Canine Mammary Neoplasia, held on November 6th and 7th, 2010 in Belo Horizonte – MG, Brazil. Academics fromseveral regions of Brazil were present and contributed to this work. After three years, a new discussion was foundnecessary in order to address important questions: 1 - Have Brazilian DVMs applied the consensus? 2 - What were the maindifficulties in applying the consensus? 3 - What were the obtained results? 4 - What were the main differences among thevarious oncology services/groups? 5 - How could the criteria be improved and uniformed? A spreadsheet that allowed datacollection and an abstract was submitted by each oncology service/group from various parts of the country. Based on theabstracts we identified the main differences in diagnosis and therapeutic conducts among the groups. These differences haveguided the discussions of the II Mammary Pathology Meeting and the publication of a second consensus that has beenrevised and updated. The II Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment of the Canine mamaryNeoplasia, was held on December 9th, 10thand 11th, 2013 in Belo Horizonte – MG, sponsored by the Laboratory ofComparative Pathology of the Federal University of Minas Gerais (UFMG), with the support of the Brazilian Associationof Veterinary Pathology (ABPV) and Brazilian Association of Veterinary Oncology (ABROVET). Academics from severalregions of Brazil were present and contributed to this work.

Consensus for the Diagnosis, Prognosis and Treatment of Canine Mammary Tumors 2013

The purpose of this paper is to establish criteria that could guide the diagnosis, prognosis and treatment of caninemammary neoplasias. It was elaborated during the Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment ofthe Canine Mammary Neoplasia, held on November 6th and 7th, 2010 in Belo Horizonte MG, Brazil. Academics fromseveral regions of Brazil were present and contributed to this work. After three years, a new discussion was foundnecessary in order to address important questions: 1 - Have Brazilian DVMs applied the consensus? 2 - What were the maindifficulties in applying the consensus? 3 - What were the obtained results? 4 - What were the main differences among thevarious oncology services/groups? 5 - How could the criteria be improved and uniformed? A spreadsheet that allowed datacollection and an abstract was submitted by each oncology service/group from various parts of the country. Based on theabstracts we identified the main differences in diagnosis and therapeutic conducts among the groups. These differences haveguided the discussions of the II Mammary Pathology Meeting and the publication of a second consensus that has beenrevised and updated. The II Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment of the Canine mamaryNeoplasia, was held on December 9th, 10thand 11th, 2013 in Belo Horizonte MG, sponsored by the Laboratory ofComparative Pathology of the Federal University of Minas Gerais (UFMG), with the support of the Brazilian Associationof Veterinary Pathology (ABPV) and Brazilian Association of Veterinary Oncology (ABROVET). Academics from severalregions of Brazil were present and contributed to this work.(AU)

Grupo PSICONVET propõe uma nova abordagem em medicina veterinária que valoriza as relações humanas

O grupo PSICONVET, recentemente criado por veterinários e psicólogos com experiência em oncologia veterinária, se dedica ao estudo do processo do adoecer por câncer em animais, considerando os aspectos físicos, emocionais e sociais dos proprietários.

Grupo PSICONVET propõe uma nova abordagem em medicina veterinária que valoriza as relações humanas

O grupo PSICONVET, recentemente criado por veterinários e psicólogos com experiência em oncologia veterinária, se dedica ao estudo do processo do adoecer por câncer em animais, considerando os aspectos físicos, emocionais e sociais dos proprietários.(AU)

Consensus for the Diagnosis, Prognosis and Treatment of Canine Mammary Tumors

The purpose of this paper is to establish criteria that could guide the diagnosis, prognosis and treatment of canine mammary neoplasias. It was elaborated during the Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment of the Canine Mammary Neoplasm, held on November 6th and 7th, 2010 in Belo Horizonte ­ MG, Brazil, sponsored by the Laboratory of Comparative Pathology ­ UFMG, with the support of the Brazilian Association of Veterinary Pathology (ABPV) and Brazilian Association of Veterinary Oncology (ABROVET). Academics from several regions of Brazil were present and contributed to this work.(AU)

Estudo in vivo de um sistema de liberação de drogas constituído por hidroxiapatita e cisplatina

The drug release system constituted by hydroxyapatite and cisplatin was tested in rats for local and systemic drug release. The side effects to treatment were: anorexia, diarrhea, epistaxe e cutaneous necrose in the implantation bed; 45% animals of test group died by treatment intoxication. Serum, renal, hepatic and muscular tissues samples were collected for cisplatin analysis of all animals that received implants, showing system's kinetics.

Um sistema de liberação constituído por hidroxiapatita e cisplatina foi testado em ratos para avaliação da liberação local e sistêmica do antineoplásico cisplatina. Os animais que receberam os implantes com a droga desenvolveram efeitos colaterais ao tratamento, sendo os mais comuns: anorexia, diarréia, epistaxe e necrose cutânea no sítio de implantação; cerca de 45% deste animais morreram, indicando intoxicação. Amostras de sangue e dos tecidos hepático, renal e muscular de todos os animais pertencentes ao experimento foram submetidas à detecção das concentrações de cisplatina, revelando a cinética de liberação da droga pelo sistema proposto.

Consensus for the diagnosis, prognosis and treatment of feline mammary tumors / Consenso para o diagnóstico, prognóstico e tratamento de tumores mamários em felinos

Mammary neoplasms are described as the third most common type of feline tumor, after haematopoietic and skin tumors, and present a challenge for clinicians because the prognosis for feline mammary tumors ranges from guarded to poor. Thus, it is necessary to define new therapeutic approaches and establish more in-depth knowledge about this disease in felines. The main aspects of the diagnosis, prognosis and treatment of feline mammary neoplasia were discussed, aiming to standardize the criteria and to serve as a guide for pathologists and veterinary clinicians.

As neoplasias mamárias são descritas como o terceiro tipo mais frequente de tumor em felinos (após as neoplasias hematopoiéticas e cutâneas) e apresentam um desafio para os clínicos devido ao prognóstico, que varia de reservado a ruim. Assim, é necessário conhecer melhor essa doença em felinos e definir novas abordagens terapêuticas. Discutiu-se os principais aspectos de diagnóstico, prognóstico e tratamento da neoplasia mamária felina, com o objetivo de padronizar os critérios e servir de guia para patologistas e clínicos veterinários.

Consensus for the diagnosis, prognosis and treatment of feline mammary tumors / Consenso para o diagnóstico, prognóstico e tratamento de tumores mamários em felinos

Mammary neoplasms are described as the third most common type of feline tumor, after haematopoietic and skin tumors, and present a challenge for clinicians because the prognosis for feline mammary tumors ranges from guarded to poor. Thus, it is necessary to define new therapeutic approaches and establish more in-depth knowledge about this disease in felines. The main aspects of the diagnosis, prognosis and treatment of feline mammary neoplasia were discussed, aiming to standardize the criteria and to serve as a guide for pathologists and veterinary clinicians.

As neoplasias mamárias são descritas como o terceiro tipo mais frequente de tumor em felinos (após as neoplasias hematopoiéticas e cutâneas) e apresentam um desafio para os clínicos devido ao prognóstico, que varia de reservado a ruim. Assim, é necessário conhecer melhor essa doença em felinos e definir novas abordagens terapêuticas. Discutiu-se os principais aspectos de diagnóstico, prognóstico e tratamento da neoplasia mamária felina, com o objetivo de padronizar os critérios e servir de guia para patologistas e clínicos veterinários.

Consensus for the diagnosis, prognosis and treatment of canine mammary tumors

The purpose of this paper is to establish criteria that could guide the diagnosis, prognosis and treatment of canine mammary neoplasias. It was elaborated during the Mammary Pathology Meeting: Diagnosis, Prognosis and Treatment of the Canine Mammary Neoplasm, held on November 6th and 7th, 2010 in Belo Horizonte MG, Brazil, sponsored by the Laboratory of Comparative Pathology UFMG, with the support of the Brazilian Association of Veterinary Pathology (ABPV) and Brazilian Association of Veterinary Oncology (ABROVET). Academics from several regions of Brazil were present and contributed to this work. 

Expressão de PRSS11, MTSS1, CLPTM1, SMYD2, NOTCH1 e RPL37A em fatias de carcinoma de mama de cadelas e correlação com resposta à doxorrubicina in vitro / Expression of PRSS11, MTSS1, CLPTM1, SMYD2, NOTCH1 and RPL37A in slices of bitch mammary cancer and correlation with response to exposure doxorubicin in vitro

Os tumores da glândula mamária constituem as neoplasias mais freqüentes em cadelas e a doxorrubicina é uma das principais drogas quimioterápicas utilizadas no tratamento deste tipo de câncer. A quimioterapia neoadjuvante com doxorrubicina possibilita a redução do tumor e permite a avaliação da resposta ao tratamento quimioterápico in vivo. A procura por marcadores preditivos de resposta tem o objetivo de identificar as pacientes responsivas e não responsivas ao tratamento com o quimioterápico de modo a permitir a indicação de uma abordagem terapêutica específica para cada paciente. A expressão de alguns trios de genes, incluindo PRSS11, MTSS1 e CLPTM1 e, PRSS11, MTSS1 e SMYD2 em mulheres com câncer de mama que receberam tratamento neoadjuvante com doxorrubicina permitiu a classificação das pacientes em sensíveis e resistentes ao tratamento. Outros genes diferencialmente expressos entre amostras consideradas sensíveis e resistentes à doxorrubicina foram NOTCH1 e RPL37A. Avaliamos no presente trabalho se a expressão de trios de genes permitia a classificação de resposta ao tratamento quimioterápico em outro modelo, constituído por carcinoma de mama de cadela, mantido em cultura de tecido na forma de fatias e exposto à doxorrubicina in vitro. A cultura de fatias de tecidos permite a manutenção da interação epitélio-mesênquima e é considerado um modelo mais próximo ao observado in vivo. Foram obtidas amostras de tumor mamário de 38 pacientes caninas atendidas no Hospital Veterinário da Faculdade de Medicina Veterinária da Universidade Metodista de São Paulo (UMESP), em São Bernardo do Campo, durante a cirurgia de mastectomia. Os proprietários deram seu consentimento livre e esclarecido para a realização do estudo. A idade mediana das pacientes foi de 10,4 anos e, 55% e 18,4% destas pacientes eram animais sem raça definida (SRD) e da raça poodle, respectivamente. Oito pacientes haviam sido submetidas previamente à cirurgia de esterilização. As pacientes apresentaram-se em estadio clínico III (39,47%), II (28,9%), I (18,4%) e IV (metástase pulmonar) (13,1%). Os carcinomas foram classificados como de arranjo cístico-papilífero (34,2%), tubular (34,2%), túbulo-papilífero (18,42%) e sólido (10,52%). Os tumores foram fatiados e cultivados na ausência e presença de doxorrubicina (1 uM) por 24 horas e, para avaliação da resposta após o tratamento, procedeu-se à contagem do número de células nas amostras tratadas e não tratadas. O tratamento com doxorrubicina promoveu uma redução média do número de células de 13,6% e, nove amostras foram consideradas responsivas, enquanto 29 não responderam ao tratamento. Amostras de tumor mantidas em cultura na ausência de doxorrubicina tiveram seu RNA extraído para determinação da expressão dos genes alvo por meio de reação de transcrição reversa e da polimerase em cadeia do DNA em tempo real. A distribuição tridimensional das amostras, baseada na expressão dos trios de genes, não permitiu a classificação das amostras em responsivas e não responsivas. Logo, a combinação da expressão de três genes alvos, incluindo PRSS11, MTSS1, CLPTM1, SMYD2, NOTCH1 e RPL37A, não separou adequadamente os tumores responsivos e não responsivos neste modelo de carcinoma mamário canino, tratado in vitro com doxorrubicina

Mammary gland tumors are the most common neoplasias of bitches and doxorubicin is one the mainstay drugs used in their treatment. Neoadjuvant chemotherapy with doxorubicin not only reduces the primary tumor as well as allows an in vivo evaluation of tumor response. Predictive markers of response, if identified, might allow a tailored treatment of each patient. In women with breast cancer submitted to neoadjuvant chemotherapy with doxorubicin, expression of groups of three genes, including PRSS11, MTSS1 and CLPTM1 and PRSS11, MTSS1 and SMYD2, classified the patients in responsive and resistant. Other genes differentially expressed between responsive and non-responsive tumors were NOTCH1 and RPL37A. We have then evaluated whether the expression of trios of these genes could allow the classification of tumors according to their response to chemotherapy, in another animal model constituted by mammary carcinoma of bitches, cultured as tissue slices and exposed to doxorrubicin in vitro. Culture of tissue slices preserves epithelial-mesenchymal interactions, in a similar way to that observed in vivo. Tumor samples were obtained from 38 canine patients treated at Hospital Veterinaria da Faculdade de Medicina Veterinária da Universidade Metodista de São Paulo (UMESP), São Bernardo do Campo, during mastectomy. Animal owners gave their informed consent to this study. Median age of patients was 10,4 years and 55% and 18,4% of them were mixed and poodle breed, respectively. Eight patients were previously spayed. Patients were classified in clinical stage III (39,47%), II (28,9%), I (18,4%) and IV (pulmonary metastasis only) (13,1%). Carcinomas were classified as cystic-papillary (34,2%), tubular (34,2%), tubular-papillary (18,42%) and solid (10,52%). Tumors were sliced and cultured in the absence or in the presence of doxorubicin (1 uM) for 24 hours and response evaluation was performed by cell counting of treated and untreated samples. Doxrubicin exposure promoted a mean reduction of 13,6% in the number and nine samples were considered responsive and 29 non-responsive. RNA was extracted from samples maintained in culture without doxorubicin and expression of target genes was evaluated by reverse transcription and real time polimerase chain reactions. Three-dimensional distribution of samples according to expression of groups of three genes could not separate responsive from non-responsive tumors. NOTCH1 and RPL37A expression was similar between responsive and resistant tumors but NOTCH1 was over expressed in poorly differentiated as compared to well differentiated carcinomas. Hence, expression of combination of three target genes, including, PRSS11, MTSS1, CLPTM1, SMYD2, NOTCH1 and RPL37A, could not correctly separate responsive from non-responsive tumors in this model of mammary carcinoma of canine species treated in vitro with doxorubicin

Estudo de um modelo experimental de liberação lenta de drogas através do implante intermuscular de hidroxiapatita sintética contendo cisplatina, em ratos

pt